Pfizer Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Meenakshi Nevatia

İcra Kurulu Başkanı

₹71.8m

Toplam tazminat

CEO maaş yüzdesi	67.9%
CEO görev süresi	1.6yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	1.2yrs
Yönetim Kurulu ortalama görev süresi	1.6yrs

Son yönetim güncellemeleri

Recent updates

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Aug 31

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Aug 07

This Is The Reason Why We Think Pfizer Limited's (NSE:PFIZER) CEO Deserves A Bump Up To Their Compensation

Aug 12

Are Institutions Heavily Invested In Pfizer Limited's (NSE:PFIZER) Shares?

Mar 10

Why Dividend Hunters Love Pfizer Limited (NSE:PFIZER)

Feb 17

CEO Tazminat Analizi

Meenakshi Nevatia'un ücretlendirmesi Pfizer'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	₹6b
Jun 30 2024	n/a	n/a	₹6b
Mar 31 2024	₹72m	₹49m	₹6b

Tazminat ve Piyasa: Meenakshi 'nin toplam tazminatı ($USD 851.56K ), Indian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 588.26K ).

Tazminat ve Kazançlar: Meenakshi şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Meenakshi Nevatia (54 yo)

1.6yrs

Görev süresi

₹71,801,316

Tazminat

Mrs. Meenakshi Nevatia serves as Non-Executive Independent Director at TeamLease Services Ltd. since July 28, 2021. Mrs. Nevatia is the Managing Director of Stryker India since October 2018.She has focuse...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Meenakshi Nevatia	MD & CEO	1.6yrs	₹71.80m	Veri yok
Amit Agarwal	Executive Director of Finance	less than a year	₹19.34m	Veri yok
Prajeet Nair	Director of Corporate Services	17.2yrs	₹11.10m	Veri yok
Pazhania Rengan	Whole-Time Director & Executive Director of Plant Operations	1.1yrs	₹9.45m	Veri yok
Anil Pattanshetty	Senior Director of Business Operations	no data	Veri yok	Veri yok
Sharad Goswami	Senior Director of Policy & Public Affairs	no data	Veri yok	Veri yok
Shilpi Singh	Director of People Experience	no data	Veri yok	Veri yok
Chaitanya Nadkarni	India Digital Client Partner Lead	1.2yrs	Veri yok	Veri yok

1.2yrs

Ortalama Görev Süresi

47yo

Ortalama Yaş

Deneyimli Yönetim: PFIZER 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.2 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Meenakshi Nevatia	MD & CEO	1.6yrs	₹71.80m	Veri yok
Amit Agarwal	Executive Director of Finance	less than a year	₹19.34m	Veri yok
Pazhania Rengan	Whole-Time Director & Executive Director of Plant Operations	1.1yrs	₹9.45m	Veri yok
Meena Ganesh	Independent Woman Director	5.7yrs	₹2.21m	Veri yok
Sunil Lalbhai	Non Executive Independent Director	9.8yrs	₹2.37m	0.0054% ₹ 13.2m
Lakshmanan Kumar	Non-Executive Independent Director	less than a year	Veri yok	Veri yok
Pradip Shah	Non-Executive Independent Chairman of the Board	24.9yrs	₹2.52m	Veri yok
Uday Khanna	Non Executive Independent Director	12.5yrs	₹2.43m	Veri yok
Sonia Singh	Independent Director	less than a year	Veri yok	Veri yok

1.6yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PFIZER 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1.6 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Pfizer Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Pfizer Limited Announces Executive Appointments, Effective November 7, 2024

High number of new directors

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Recent updates

Pfizer Limited Announces Executive Appointments, Effective November 7, 2024

Second quarter 2025 earnings released: EPS: ₹34.61 (vs ₹32.56 in 2Q 2024)

High number of new directors

We Think Pfizer (NSE:PFIZER) Can Stay On Top Of Its Debt

Pfizer Limited Approves to Declare A Dividend for the Financial Year Ended March 31, 2024

Dividend of ₹35.00 announced

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Pfizer Limited, Annual General Meeting, Aug 28, 2024

Subdued Growth No Barrier To Pfizer Limited (NSE:PFIZER) With Shares Advancing 25%

Price target increased by 11% to ₹5,477

First quarter 2025 earnings released: EPS: ₹32.94 (vs ₹20.44 in 1Q 2024)

Pfizer Limited to Report Q1, 2025 Results on Jul 29, 2024

Weak Statutory Earnings May Not Tell The Whole Story For Pfizer (NSE:PFIZER)

Full year 2024 earnings released: EPS: ₹121 (vs ₹136 in FY 2023)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2024, Payable on or Before September 6, 2024

Pfizer Limited to Report Q4, 2024 Results on May 17, 2024

Pfizer Limited Appoints Amit Agarwal as Chief Financial Officer

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Pfizer (NSE:PFIZER) Has A Pretty Healthy Balance Sheet

Third quarter 2024 earnings released: EPS: ₹28.42 (vs ₹32.93 in 3Q 2023)

Pfizer Limited Informs Satyen Amin, Lead - Market Access Tenders His Resignation from Employment, with Effect from March 31, 2024

Pfizer Limited to Report Q3, 2024 Results on Feb 09, 2024

Pfizer Limited's (NSE:PFIZER) Business Is Yet to Catch Up With Its Share Price

Pfizer Limited Appoints Ms. Aditi Mehta as Category Lead, Vaccines Effective December 1, 2023

Pfizer Limited Announces Resignation of Mr. Milind Patil as Director with Effect from Close of Business on November 13, 2023

Pfizer Limited Announces Resignation of Samir Kazi as Director from the Board of Directors

Second quarter 2024 earnings released: EPS: ₹32.56 (vs ₹67.99 in 2Q 2023)

Pfizer Limited to Report Q2, 2024 Results on Oct 28, 2023

Pfizer Limited Appoints Chaitanya Nadkarni as India Digital Client Partner Lead

Pfizer Limited Approves A Final Dividend for the Financial Year Ended March 31, 2023

New major risk - Revenue and earnings growth

Pfizer Limited Announces Change in Management, Effective September 1, 2023

Pfizer Limited to Report Q1, 2024 Results on Aug 11, 2023

Upcoming dividend of ₹40.00 per share at 0.9% yield

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited, Annual General Meeting, Aug 18, 2023

Pfizer Limited Proposes Final Dividend for the Financial Year Ended March 31, 2023

Pfizer Limited Initiates Voluntary Recall Of Magnex 1gm, 2gm, Magnex Forte 1.5gm, 3gm, Zosyn 4.5gm and Magnamycin 250mg, 1gm, 2gm Injections

Price target decreased by 7.9% to ₹4,595

Pfizer Limited Recommends A Final Dividend for the Financial Year Ended March 31, 2023, Payable on or Before September 16, 2023

Full year 2023 earnings released: EPS: ₹136 (vs ₹134 in FY 2022)

Pfizer Limited to Report Fiscal Year 2023 Results on May 15, 2023

Here's Why Pfizer (NSE:PFIZER) Can Manage Its Debt Responsibly

Third quarter 2023 earnings released: EPS: ₹32.93 (vs ₹31.46 in 3Q 2022)

Pfizer India Appoints Meenakshi Nevatia as CEO

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Insufficient new directors

Second quarter 2023 earnings released: EPS: ₹67.99 (vs ₹31.25 in 2Q 2022)

Upcoming dividend of ₹30.00 per share

Pfizer Limited Announces Interim (Special) Dividend for the Financial Year Ending March 31, 2023, Payable on or Before September 30, 2022

Pfizer Limited Approves Declaration of Dividend for the Financial Year Ended March 31, 2022

Upcoming dividend of ₹35.00 per share

Pfizer Announces Resignation of S. Sridhar as Managing Director

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

First quarter 2023 earnings released

Pfizer Limited Proposes Dividend for the Financial Year Ended March 31, 2022

Mylan Pharmaceuticals Private Limited completed the acquisition of off-patent branded and generic established medicines business from Pfizer Limited (BSE:500680).

Pfizer Limited to Report Q1, 2023 Results on Aug 05, 2022

A Look At The Intrinsic Value Of Pfizer Limited (NSE:PFIZER)

Now 20% undervalued after recent price drop

Price target decreased to ₹5,201

Now 21% undervalued after recent price drop

Full year 2022 earnings released: EPS: ₹134 (vs ₹109 in FY 2021)

Pfizer Limited Recommends Dividend for the Financial Year Ended March 31, 2022, Payable on or before September 23, 2022

Price target decreased to ₹5,654

Insufficient new directors

Insufficient new directors

Pfizer (NSE:PFIZER) Could Easily Take On More Debt

Pfizer and FDA Dropped Data Bombshell on Covid Vaccine Consumers